Physician profile
David W Chia
NPI 1215970892
$2,686.52
in general payments reported to CMS, 2019-2025
29 companies · $630 in 2025
The $630 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $435 · 2020: $48.60 · 2021: $339 · 2022: $406 · 2023: $368 · 2024: $461 · 2025: $630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,458.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $302.78 | 2022-2025 | Argos, Hydrus Microstent, Clareon Panoptix Pro |
| New World Medical,INC. | $283.14 | 2019 | |
| Genentech USA, INC. | $254.64 | 2021-2022 | |
| Amgen INC. | $238.03 | 2024-2025 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $237.28 | 2022-2024 | Tecnis Simplicity, Tecnis Iol, Veritas Vision System |
| Sun Pharmaceutical Industries INC. | $181.61 | 2019-2025 | Cequa |
| Immunogen, INC. | $136.14 | 2023 | Elahere |
| Spark Therapeutics, INC. | $125.00 | 2021 | |
| Nova Eye, INC. | $112.97 | 2024-2025 | |
| Abbvie INC. | $103.95 | 2024-2025 | |
| Coopervision INC. | $76.08 | 2022-2025 | Misight Contact Lens |
| Aerie Pharmaceuticals, INC. | $74.44 | 2020-2021 | |
| Allergan, INC. | $59.37 | 2020-2022 | |
| Rxsight INC | $58.36 | 2023-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Horizon Therapeutics Plc | $57.89 | 2022-2023 | Tepezza |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $48.58 | 2024 | Xdemvy |
| Alcon Research LLC | $42.76 | 2019 | |
| Shire North American Group INC | $38.98 | 2019 | |
| Optos, INC. | $31.33 | 2019 | |
| Pfizer INC. | $29.27 | 2025 | |
| Oyster Point Pharma, INC. | $27.49 | 2023 | Tyrvaya |
| Johnson & Johnson Vision Care, INC. | $25.46 | 2019 | |
| Kala Pharmaceuticals, INC. | $24.49 | 2021 | |
| Thea Pharma INC. | $23.47 | 2023 | |
| Ivantis, INC | $21.09 | 2020 | |
| Bausch & Lomb Americas INC. | $20.51 | 2023 | Stellaris |
| Glaukos Corporation | $19.69 | 2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Harrow Eye, LLC | $17.62 | 2025 | |
| Heidelberg Engineering, INC. | $14.10 | 2025 | Spectralis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Chia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.